MAPK7 and colorectal cancer: Thus, among others, ERK5 inhibitor XMD8-92 improves the cytotoxicity of docetaxel and/or doxorubicin in lung [51], triple negative breast [52] and squamous skin [53] cancer cells and tumors, as well as the antitumor action of 5’-fluoroacil in p53-dependent colorectal cancer cells [54].